Recent guidelines on cancer screening have provided not only more screening options but also conflicting recommendations. Thus, patients, with their clinicians' support, must decide whether to get screened, which modality to use, and how often to undergo screening. Decision aids could potentially lead to better shared decision-making regarding screening between the patient and the clinician. A total of 73 decision aids concerning screening for breast, cervical, colorectal, and prostate cancers were reviewed. The goal of this review was to assess the effectiveness of such decision aids, examine areas in need of more research, and determine how the decision aids can be currently applied in the real-world setting. Most studies used sound study designs. Significant variation existed in the setting, theoretical framework, and measured outcomes. Just over one-third of the decision aids included an explicit values clarification. Other than knowledge, little consistency was noted with regard to which patient attributes were measured as outcomes. Few studies actually measured shared decision-making. Little information was available regarding the feasibility and outcomes of integrating decision aids into practice. In this review, the implications for future research, as well as what clinicians can do now to incorporate decision aids into their practice, are discussed. CA Cancer J Clin 2013;63:193-214.
Introduction
In recent years, screening strategies for many conditions have become increasingly complex. Guidelines now recommend more options for cancer screening. Some guidelines also have conflicting recommendations. Thus, patients, with their clinicians' support, must decide whether to get screened, which modality to choose, and how often to undergo screening. These considerations are foundational to informing patients' preferences, and make these decisions ''preference-sensitive.'' Decision aids could be an ideal tool to help patients understand their risk of developing a particular cancer, the screening options available (including the possible option of not getting screened), recommended screening time intervals, and their own values and preferences for a particular option and outcome. Consequently, decision aids have proliferated in recent years. They usually include information on the disease/condition and the associated tests/treatments, probabilities of outcomes (benefits and harms) for each test/treatment option, and some form of a values clarification exercise to help patients determine which option would best match their values. Decision aids may also include guidance or coaching in the process of decision-making. 1 They are not meant to replace the discussion between the patient and his/her clinician, but rather to complement it.
Cancer screening decisions are increasingly recognized as being preference-sensitive, due to the increased recognition of harms from sequelae of screening, the need to tailor screening recommendations to the patient's risk, the multiple options available in some screening tests, and conflicting recommendations from guidelines. The potential of harm from screening was highlighted recently when the US Preventive Services Task Force recommended against routine screening for prostate cancer. 2 They made this recommendation while other guidelines had similarly weighed the benefits and harms of prostate cancer screening and instead of discouraging screening, stressed shared decision-making between the patient and the clinician to decide whether the patient should undergo screening. 3 Other cancer screenings involve preference-sensitive decisions as well, such as colorectal cancer screening, in which options include stool blood testing, flexible sigmoidoscopy, colonoscopy, and other modalities. 4, 5 Even screening for cancers that traditionally are without many options has become more complex, with some recent guidelines recommending shared decisionmaking between the patient and clinician to determine whether to get screened for breast cancer among women aged 40 years to 49 years, 6 consideration of magnetic resonance imaging for women with a high risk of breast cancer, 7 and the option of cytological testing every 3 years or cytological testing plus human papillomavirus testing every 5 years to screen for cervical cancer. 8 The purpose of this review is to summarize what is known about the effect of decision aids on cancer screening, and to explore areas in which more information is needed to fully understand the impact of decision aids on the process and outcomes of shared decision-making between the patient and the clinician.
Materials and Methods

Screened Cancers
We focused our attention on cancers for which the national guidelines recommend screening the general population. [4] [5] [6] [7] [8] Thus, we selected the decision aids for the screening of breast, cervical, and colorectal cancers. In addition, we looked at genetic testing for women considered to be at high risk of breast cancer, since it was believed to be an important option for selected high-risk women desiring further screening evaluation for breast cancer. Finally, we included prostate cancer screening in our search, since all guidelines except those by the US Preventive Services Task Force recommend that at least a discussion occur between the patient and clinician to decide whether screening for prostate cancer would be warranted in the particular patient. 2, 3 Study Identification The MEDLINE, CINAHL, EMBASE, and CCRCT searches were conducted via the Ovid Technologies Inc interface. The majority of the topical search retrieval was obtained via MEDLINE using Medical Subject Headings, including ''breast neoplasms;'' ''colorectal neoplasms;'' ''uterine cervical neoplasms;'' ''prostatic neoplasms;'' ''mass screening;'' ''decision support techniques;'' ''decisionmaking;'' ''decision-making, computer-assisted;'' and ''decision support systems, clinical.'' In addition, limited text word searching was used. Corresponding keyword searches with Boolean syntax were conducted in CCRCT and SCI.
Theoretical Framework
In order to provide a theoretical organizing framework for our evaluation of studies, we have adapted the Integrative Model of Behavior by Frosch et al, which combines the 4 theories most frequently applied in health behavior research within the past 30 years (Theory of Reasoned Action, Theory of Planned Behavior, Health Belief Model, and Social Cognitive Theory). 9 This theory combines measurable constructs of behavior (attitudes, perceived social norms, self-efficacy, and behavioral intention) to the actual behavior. Because an important aspect of decision aids is the clarification of preferences and values, we have added that component, as well as how the subsequent patient/clinician discussion ensues in terms of shared decision-making and patient/clinician concordance (match between the patient's preferred screening option and the clinician's recommended option). 10, 11 Figure 1 illustrates our adapted framework with relevant examples. Applied to the topic of this review, the use of decision aids to affect the patient's behavior regarding cancer screening, this theoretical framework provides a helpful structure for understanding where decision aids intervene and exert their influence on screening behavior. It influenced the selection of the decision attributes evaluated. Our analysis focused on understanding the impact of the decision aid on patient's attributes, shared decision-making, and patient/ clinician concordance. Our model suggests that all of these are important to understanding the impact on patient screening behavior and determined the questions posed in the review.
Procedure
Two evaluators (M.J. and M.R.) reviewed each of the identified articles independently to determine if the study was relevant to the topic. Publications were excluded if the article was a review; an opinion article; an abstract; descriptive of a new decision aid without an intervention/ trial component; or measured for usability but not for effects on patient knowledge, attitude, or behavior. Articles also were excluded if the study patients had an established cancer diagnosis, since our focus was on cancer screening. For the same reason, we excluded the study if it included treatment (eg, prophylactic mastectomy) as an option.
We selected the studies if the decision aid contained information on the disease/condition and the associated tests/treatments and probabilities of outcomes (benefits and harms) for each test/treatment option. 1 We excluded studies in which the intervention was provided solely through a health care professional (eg, a script) since decision aids by definition are separate tools that complement the patient/clinician discussion and aid in decision-making. We did not directly contact the study authors but thoroughly reviewed the relevant articles for the original and detailed description of the decision aid intervention and, when necessary, reviewed the references for the original description of the intervention. We also directly accessed the decision aids if available. We included preintervention/postintervention and other nonrandomized designs as well as randomized controlled designs because we wanted to be as inclusive as possible to capture innovative decision aids. For that reason, we also included pilot studies as long as they had intervention and evaluation components. A number of publications were found that were duplicate reports of a single study or serial reports from the same study. In these cases, the study was counted as one, although all pertinent publications were reviewed. The cited literature referenced in relevant studies was also examined for possible additional studies.
Study Questions/Measures
We categorized the measures into the following questions.
1) Does the Decision Aid Used in the Study Address the Issues That Need to Be Addressed in a Screening Decision Aid? 1 We determined whether the decision aid included information on the cancer and the screening test options involved, probabilities of outcomes including the benefits and harms for each option, an explicit value clarifications exercise to help the patient determine which option would best match his/her values, and guidance or coaching in the process of decision-making. For values clarification, we specifically looked for the existence of a process (eg, exercise) that would actively engage the patient in clarifying his/her values. For guidance or coaching, we examined the specific ways in which the decision aid or the study addressed the discussion with the clinician.
2) Does the Study Measure the Effect of the Decision Aid on the Patient Attributes Established in the Theories of Behavioral Research?
We determined whether the study measured the patient's knowledge, attitude, perceived normative pressure, selfefficacy, preference clarification, and intent regarding the cancer and cancer screening test in question. Here, preference is different from values in that ''preference'' is defined as an actual preference for a certain option.
3) Does the Study Address the Impact of the Decision Aid on the Patient Behavior in Question?
We determined whether the decision aid increased or decreased patient uptake of the particular cancer screening test, and whether it was by subjective (eg, patient self-report) or objective (eg, chart review) report. We also determined whether the completed cancer screening test was the option that the patient had originally chosen at the time of the decision aid use.
4) Does the Study Address the Effect of the Decision
Aid on the Subsequent Discussion Between the Patient and His/Her Clinician? We determined whether the study addressed the subsequent discussion between the patient and his/her clinician (ie, shared decision-making) and whether it was affected by use of the decision aid. We also determined whether there was concordance between the patient and the clinician (ie, whether they agreed on a particular cancer screening test option). 11 In addition, we determined whether any other factors after the patient/clinician encounter (eg, family members, media) were considered as having influenced the patient's screening behavior.
5) Does the Decision Aid Appear to Be Applicable in Real-World Practice?
We determined the feasibility of applying the decision aid in real-world practice through the study's setting and patient selection, and whether the decision aid was standalone or done in conjunction with other clinical activities.
We also determined whether the study addressed the ability of the decision aid to be used in repeat screening and whether cost analysis was performed.
Determination of Outcomes
For the outcomes, only those outcomes based on intention to treat were considered when the intention-to-treat numbers were available. In addition, when the P value was available, only those outcomes that were statistically significant at P < .05 were considered to be meaningfully different. Outcomes were compared between groups for the studies that were randomized or factorial in design.
Outcomes were compared before and after the intervention for those studies with a preintervention/postintervention design.
Specific Areas Addressed Based on the 5 Questions
The 2 evaluators independently read each publication to determine each of the following areas: 1) primary author and year; 2) target cancer for screening; 3) cancer screening options addressed; 4) target population and characteristics (eg, patient, clinician, or both); 5) study design; 6) setting (eg, community or academic); 7) follow-up duration; 8) content of the decision aid (theoretical framework, provision of information, risks and benefits, values clarification exercise, guidance on decision-making and communication, provision of a no-screening option, and discussion of when to stop screening); 9) patient outcomes assessed for the decision aid (knowledge, attitude, subjective norm, self-efficacy, preference clarification, intention, and screening behavior) as well as whether it was a self-report or an observational review; 10) patient/ clinician outcomes assessed for the decision aid (shared decision-making and concordance); and 11) practice outcomes assessed for the decision aid (postvisit factors [eg, effect of media, family, and friends], incorporation of the decision aid into practice [eg, meaningful use], effect of the decision aid on repeated screening, and cost analysis).
The evaluators met as a group to review their classifications, discussed any disagreements, and arrived at a consensus of opinion for all studies.
Results
Seventy-nine studies were identified that evaluated 73 decision aids meeting the criteria outlined above. Only 2 decision aids dealt with cervical cancer screening. 12, 13 Eighteen decision aids dealt with breast cancer screening, 9 of which concerned mammography for the general population [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] and 9 of which concerned genetic testing for those considered to be at high risk of breast cancer based on family history and other information. [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] Twenty-one decision aids dealt with colorectal cancer screening ; 29 dealt with prostate cancer screening ; 2 decision aids dealt with both colorectal and prostate cancer screening 88, 89 ; and one decision aid dealt with all 4 cancer screenings: breast, cervical, colorectal, and prostate. 90 Characteristics of the Identified Studies [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] and prostate-specific antigen, respectively. The breast self-examination and clinical breast examination in one decision aid on mammography screening were not considered options but rather came as a set with the mammogram. 14 [55] [56] [57] [60] [61] [62] [63] [64] [65] [66] [67] [68] [72] [73] [74] [75] [76] [77] [78] [84] [85] [86] and all decision aids on multiple cancer screening (n¼3) 89, 90 did not incorporate a theoretical framework. A few had adopted a formative approach (eg, interviews, focus groups, and expert feedback; 24 of 73 decision aids), 16, 17, 22, 29, 31, 32, 34, 36, 40, 42, 44, 46, 48, 52, 53, 55, 59, 60, 62, 63, 70, 71, 83, 88, 89 but others seemed to have moved relatively quickly from literature and expert review to the creation of the tool and pretesting.
Variation was seen in the methods of values clarification, in which the patient actively engages in a process where his or her values regarding the screening test(s) are clarified. The patient had to be actively involved in such an exercise, such as writing out the pros and cons (in cases of paper-based decision aids) or clicking on choices (in the case of Web-based and other interactive decision aids). Fewer than one-half of the decision aids used these exercises (27 of 73 decision aids). 18, 19, [21] [22] [23] 25, 27, 28, 31, 32, 36, [38] [39] [40] 43, 45, 48, 49, 52, 54, 58, 65, 68, 69, 78, [80] [81] [82] [83] [84] Neither of the 2 decision aids that addressed cervical cancer screening 12, 13 nor any of the 3 decision aids that addressed multiple cancer screenings [88] [89] [90] incorporated them.
Variation was also seen in the methods of providing guidance for making decisions and communicating with the clinician. Some were simply a statement of recommendation to speak to a clinician. 14 Others provided a list of questions to ask the clinician 17, 49, 84 ; some of these provided a list customized to the specific patient. 22, 31, 82 Other studies attempted to facilitate communication through practice-based interventions, such as having the patient use the decision aid immediately before or during genetic counseling [30] [31] [32] or providing color codes in the chart to let the clinicians know of the patient's readiness for colorectal cancer screening. 34, 41, 50, 51 In all, 43 of 73 decision aids, including all 3 decision aids on multiple cancer screening, [88] [89] [90] provided the guidance on communicating with clinicians. Neither of the 2 decision aids on cervical cancer screening did so. 12, 13 Regarding provision of a ''no screening'' option, all decision aids involving breast cancer genetic testing [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] and all but 2 decision aids involving prostate cancer screening (including those targeting multiple cancers) [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [88] [89] [90] provided such an option. This is understandable since the choice in these cases is to undergo the screening test or not. This option was also available in 4 of 9 breast cancer mammography screening [18] [19] [20] [21] 23 and 6 of 21 colorectal cancer screening decision aids. 35, 36, 42, 48, 49, 53 Neither of the 2 cervical cancer screening decision aids provided it. 12, 13 Of all the decision aids, only one on mammography screening 21 and one on prostate cancer screening 56, 57 dealt with the question of when to stop screening.
Patient Outcomes Assessed for the Decision Aids
Knowledge was assessed in a majority of the decision aids (52 of 73 decision aids) ( Table 3) . Twelve decision aids had no effect on knowledge. 15, 20, 29, 38, 41, 42, 47, 64, 70, 71, 76, 78, 87 Attitude was assessed in 35 of 73 decision aids. There was no impact on attitude in 4 breast cancer mammography decision aids. 15, [18] [19] [20] 23 Of the 7 breast cancer genetic testing studies, one showed an increase 26 and 2 showed a decrease in perceived personal risk, 24, 27, 28 one showed a decrease in positive belief, 33 and one showed a decrease in worry. 30 The remaining 2 demonstrated no difference. 31, 32 One decision aid on cervical cancer screening showed decreased perception of procedural and cognitive barriers and increased perceived benefit of the Papanicolaou test. 13 Of the 8 colorectal cancer screening decision aids for which attitude was measured, 38, 42, 43, 45, 47, 49, 53, 54 there was little impact. Studies including a ''no screening'' option resulted in less clarity concerning perceived benefits 42 and a less positive attitude overall toward colorectal cancer screening. 49 The 14 prostate cancer screening decision aids in which the attitude was measured, all but one of which contained a ''no screening'' option, showed overall a more negative attitude toward prostate cancer screening. [59] [60] [61] 65, 68, 72, 76, 77, [80] [81] [82] [84] [85] [86] [87] Subjective norm, or perceived social pressure to engage or not to engage in a behavior, was addressed in just 5 of 73 decision aids.
31,32,47,54,88 All but one of them (subjective norm was found to decrease with one decision aid on multiple cancer screenings 88 ) showed no effect. Self-efficacy was addressed in 10 of 73 decision aids. It was increased in 5 decision aids, 13, 38, 54, 65, 82 decreased in 2, 60, 88 and not different in 3 decision aids. 45, 65, 83 Preference clarification was assessed in 31 of 73 decision aids. 16, 21, 23, [31] [32] [33] 36, [40] [41] [42] [43] 45, [48] [49] [50] 52, 53, 55, 60, 61, 64, 65, 68, 74, [76] [77] [78] [80] [81] [82] [83] [84] In 19 of these, preference clarification was assessed through decreased decisional conflict, greater values clarity (eg, a subscale of the decisional conflict scale), or greater informed choice (a combination of knowledge, values clarity, and intent). 21, 23, 31, 32, 36, 41, 42, 45, 48, 49, 53, [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] Intention was measured in 40 of 73 decision aids. Nine decision aids led to an increased intention to get screened; 7 of these concerned colorectal cancer screening, 34, 38, 46, 48, 50, 52, 54 and one each dealt with cervical cancer screening 13 and prostate cancer screening. 86 A decreased intention to undergo screening was noted in 13 decision aids: 8 of these dealt with prostate cancer screening, [55] [56] [57] 60, 62, 63, 66, 70, 71, 80, 81, 84 ; 2 with breast cancer genetic testing 29, 33 ; and one each concerned mammographic screening, 23 cervical cancer screening, 12 and multiple cancer screening. 88 No difference in intention was noted in 18 decision aids. 21, [24] [25] [26] [27] [28] 35, 41, 42, 45, 47, 65, 67, 68, 72, 76, 82, 83, 87 Screening behavior was assessed in 36 of 73 decision aids. Thirteen decision aids led to an increase in screening (7 colorectal cancer screening decision aids, 34 ). Eighteen decision aids showed no difference in screening.
Patient/Clinician and Practice Outcomes Assessed for the Decision Aid
Many of the studies on decision aids did not address any of the issues related to shared decision-making, concordance, postvisit factors, incorporation into practice, impact of the decision aid, and cost analysis. Eighteen of 73 decision aids were assessed for their effect on shared decision-making. No trend toward an increased degree of shared decision-making was noted in these 18 studies. All studies used patient selfreport and did not use observational measures, such as audiorecorded data, to assess shared decision-making. Of note, none of the decision aids on mammography or cervical cancer screening addressed shared decision-making as a measure. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Concordance, or whether the patient and clinician agreed on a particular cancer screening test option, was addressed in just 5 of 73 decision aids. 31, 32, 40, 52, 68 It was high in the 2 decision aids on breast cancer genetic testing, 31 ,32 but only modest in the 2 decision aids concerning colorectal cancer screening. 40, 52 The single decision aid study on prostate cancer screening that addressed concordance noted that it was affected by the format of the decision aid. 68 Only 2 of 73 decision aid studies, both dealing with breast cancer genetic testing, considered postvisit factors as potential mediators of screening behavior. 31, 32 In both studies, a patient's sharing of received materials with family was assessed, with one study noting an increase 31 and the other noting no difference. 32 None of the decision aids was assessed for the effect of media, the referral process for testing, or other factors that may have also affected screening. Eleven of 73 decision aids were also assessed for incorporation into practice: 5 on breast cancer genetic testing, 25, [29] [30] [31] [32] 4 on colorectal cancer screening, 34, 41, 50, 51 and 2 on multiple cancer screening. 89, 90 The studies generally attempted to link a clinician visit with the decision aid through timing 30 or modifications to the patient's chart. 31, 41, 50 Four studies specifically dealt with how to incorporate the decision aid into usual practice. 32, 51, 89, 90 
Discussion
Only 73 decision aids were found to have published data using our search strategies. This is a rather modest number given the many recommendations to use such tools. 91, 92 Most decision aids were evaluated with a sound research design, such as randomized controlled, 2 Â 2 factorial, and Solomon 4-group designs. The use of a theoretical framework and the description of how the decision aid was developed were more variable. Our finding that just 41 of 73 decision aids (56%) used a theoretical framework is better than the findings from the review by Durand et al, in which 17 of 50 studies (34%) were shown to have used a theoretical framework in the development of decision aids for screening and treatment. 93 However, the difference is likely due to the inclusion of other diseases and treatments in their review. When the studies in the review by Durand et al are limited to decision aids on cancer screening, 8 of 15 studies (53%) used a theoretical framework, a figure similar to ours. Having a theoretical framework is important to determine how and why a particular decision aid is effective, since it is from this framework that the measurable outcomes are derived. The presence of a framework, however, did not necessarily mean that the development of the decision aid was well described. In particular, fewer than one-third of the studies contained enough information for the reviewers to be able to determine that a formative approach had been adopted. The reviewed decision aids uniformly provided information about the cancer and screening tests and the benefits and risks of each screening option. In contrast, just over one-third of the decision aids provided explicit values clarification exercises. Values clarification may be explicit in that patient actions are required through an exercise, such as writing down pros and cons, answering surveys to create tailored messages, and an analytical hierarchy process. It could also be implicit, such as when comparing the options in a table. It is currently unclear whether the explicit method is superior to the implicit method, although there is emerging evidence that the former may be better. 94 With regard to guidance on making decisions and communicating with the clinician, only a few decision aids were found to provide recommendations that were tailored to the patient. This may be better provided as part of a practice-based intervention, in which the decision aid is just one of the interventions, rather than attempting to put everything into a stand-alone tool. 90 Other than the decision aids on breast cancer genetic testing and prostate cancer screening, in which the decision in question is whether to be screened, few studies provided the option of ''no screening.'' For the established decision aids on cancer screening to be effective (eg, cervical cancer screening, colorectal cancer screening), the issue of whether to include the option of no testing may be a delicate balance between patient autonomy and beneficence. 95 Interestingly, of the 6 colorectal cancer screening decision aids in which this option was included, only one showed a clear decrease in screening uptake. 49 This may have occurred because the decision aid in question provided a choice of getting a stool blood test versus not getting one, whereas in the other 5 studies, the ''no screening'' option was listed along with 2 or more screening options. Thus, the study by Smith et al 49 is similar to the studies of decision aids on breast cancer genetic testing and prostate cancer screening, which have been shown to decrease the test uptake. It is of interest to note that the decision aid that specifically addressed how the inclusion of a ''no screening'' option along with multiple screening options for colorectal cancer affected patient intent showed no difference, but also indicated that the patients presented with a ''no screening'' option felt less clarity in making a decision. 42 Few studies included information on when to stop screening. For breast cancer genetic testing, this is understandable, since it is a one-time test. For others, recommendations concerning at what age to stop screening did not become available until the recent guidelines. In addition, since most studies focused on a single decisionmaking event and not multiple decisions over time, and typically had a cap on the maximum age for inclusion, the issue may not have been relevant. From the perspective of incorporating a decision aid into daily practice, it may be more feasible to have a separate discussion on when to stop screening prompted through a clinician reminder system. 96 Other than knowledge, there was little consistency in the patient attributes measured as outcomes in the studies. The attributes in the Health Belief Model (eg, perceived benefit, perceived risk) were used most frequently when assessing the positive or negative attitudes toward screening. Subjective norm and self-efficacy were rarely measured. These measures would be important in determining the contribution of the decision aids to the decision autonomy of the patients after their use. For example, patients who perceive greater social pressure (either through their family, peers, or clinician) may still be affected by others' advice after using the decision aid.
Preference clarification was most commonly assessed by the Decisional Conflict Scale. 97 This scale includes subscales of ''Informed'' and ''Values Clarity,'' which may be particularly relevant when measuring the effects of decision aids. Some studies have adopted an informed choice measurement, which is believed to be a better measure of decision quality and combines the scores of knowledge, values clarity, and intent or behavior. 98 This measurement may be increasingly adopted in the future studies on decision aids. Just approximately one-half of the studies actually measured screening uptake as an outcome. Of these, greater than one-half were by patient self-report after a variable period of time. This may be problematic, since patients tend to overreport screening behavior. 99, 100 Other studies used patient intention rather than screening uptake as the final outcome, which has an even lower correlation with actual behavior than self-report. 101 Of note, 10 of 73 decision aids had neither intention nor behavior as their outcome. 15, 16, 20, 43, 64, 75, 77, 78, 85, 89 There is little justification not to measure one or both of these outcomes at this time.
Few studies have actually addressed patient/clinician communication subsequent to use of a decision aid. Since the decision aids are purported to improve shared decisionmaking, it is surprising that there are few objective data to support such claims. 1, 102 The studies that did measure some component of shared decision-making based their measurements on patient self-report. Unfortunately, they are not considered to be sufficiently objective [103] [104] [105] [106] [107] The use of these measures would require recording of the patient/clinician encounter, which would also make them available for qualitative and mixed-methods analyses, thereby enriching the findings. Intriguing questions that may be answered through these processes include: How is patient/physician communication affected by the use of decision aids? Is sharing decisionmaking between the patient and physician always positively impacted by decision aids? Are there instances in which patient activation by decision aids may be deleterious (eg, patient strongly inclined to use stool blood test for colorectal cancer screening but the physician strongly recommends colonoscopy; frustrated, the patient decides not to get screened)?
Even rarer than the measurement of shared decisionmaking was the measurement of concordance. Since shared decision-making allows for a decision to be deferred when an agreement is not met, it would be important to assess whether the decision aid led to an increase in agreement between the patient and the clinician. Current cancer screening literature, particularly that regarding colorectal cancer screening, reveals a potential negative impact on shared decision-making as the clinicians increasingly prefer colonoscopy as the test of choice, to the exclusion of considering patient preference. 108 Thus, whether patients activated through decision aids could steer the clinicians toward a more shared decision-making approach and increased concordance would be an important outcome measure. Postvisit factors, such as the influence of media and family and the ease of the referral process for subsequent testing, were addressed so rarely as to be inconsequential.
The study settings and populations in which the decision aids were used were sufficiently variable. Thus, these decision aids would likely lead to similar results in other settings. More problematic was that the decision aids tended to be stand-alone and not integrated into the daily practice routine. This would likely limit their practical use. When intention-to-treat analysis is adopted, many studies show a very small to negligible effect by the decision aids, due to the low usage by patients. In addition, studies have shown that although clinicians like the concept of decision aids, they actually rarely use them in settings that are conducive to shared decision-making and where publicly accessible decision aids are available. 109 Unless the decision aids incorporate risk assessment and tailor their values clarification exercises accordingly (eg, moving from multiple options in average-risk patients to recommending colonoscopy in patients at increased risk in colorectal cancer screening), or a reminder system exists that could link patients to decision aids based on their profile, clinicians may perceive the decision aids to be too cumbersome. These barriers may not be overcome unless a more comprehensive, practice-based approach is adopted. [110] [111] [112] [113] An excellent example of using a practicebased approach in a real-world setting is a recent publication from a large health system in Washington State. Their organizational effort to implement decision aids for patients facing hip and knee arthritis and joint replacement surgery was associated with 26% fewer hip replacement surgeries, 38% fewer knee replacements, and 12% to 21% lower costs over 6 months. 114 Currently, only one study has attempted an improvement in cancer screening through practice-wide intervention, including the use of decision aids. 90 What Can Practicing Physicians Do?
First, physicians need to accept that cancer screening has elements that are sensitive to patient preferences and choice. Second, it would be helpful for physicians to know how to access useful decision aids. An example is the repository of decision aids available from the Ottawa Hospital Research Institute in Ontario, Canada. Their Web site (decisionaid.ohri.ca/AZlist.html) contains links to high-quality decision aids in various topics, including screening for all of the cancers discussed in this review. Third, many organizations offer free information to patients in a way that may still provide them with desired information on how the cancer screening tests work and their risks and benefits. An example would be the American Cancer Society Web site (cancer.org), which provides the latest information on screening for breast, cervical, colorectal, and prostate cancers, among others. The barrier is how and when one uses these existing tools in the course of a busy day. It will likely be either before or after the physician visit, thus unloading time and effort from the visit itself. Fourth, the state-of-the-art interactive decision aid may not be feasible in a real-world practice setting at this time. This reality may be reflected in the fact that many of even the more recent studies use print rather than Web-based decision aids.
With the increasing use of electronic medical records linked to patient portals, as well as advances in mobile telephones and their applications, decision aids that are accessible and easily understandable may become more available in a timely manner to patients in the near future. The features used to evaluate the studies in this review would serve as an excellent checklist for physicians to use when examining such tools.
Limitations
First, despite an exhaustive attempt to identify all published English language studies on this topic, due to the differences in current indexing practices in and among the electronic databases, we cannot ensure that we have examined all of the published English language works in this subject area. Some studies were published in abstract form only and could not be included due to a lack of detail. Second, there are likely to be unpublished studies relevant to this area. It is unknown if the results of these studies would sway the assessment given that most unpublished studies contain negative findings. Third, the published data lacked significant details regarding how the decision aids work. We searched for relevant articles on their development and accessed the original tools if available, but this was possible in only a minority of the cases. It may be that some decision aids actually possess the features that we had concluded were lacking. Fourth, the published data lacked detailed information on how the decision aids were developed and how the outcomes measures were determined. Because of this, we did not rigidly apply the International Patient Decision Aids Standards (IPDAS) criteria to the decision aids. Of note, IPDAS is an internationally recognized scoring system of decision aid quality. 115 It measures the quality of the decision aids in 10 dimensions, including information provided, description of probabilities, and availability of decision guidance. It is increasingly influential in determining how decision aids should be developed. Finally, our approach to evaluating these studies highlights the vast array of complex data that need to be gathered and analyzed to adequately address the topics that were considered. For many investigators, collecting such a quantity and diversity of data may have been beyond their funding, resources, or skill set. It also may not be well reviewed at study review sections that place a priority on focused research questions. In addition, many investigators' research teams lack expertise in certain areas not addressed. The collection of adequate data also may create too much of a burden on the study participants, which would limit accrual and follow-up. Thus, the ideal scenario would be a series of studies expanding the focus and further refining the intervention, which we did not find.
Unique Features of Our Review
Many high-quality reviews are available on decision aids. 116, 117 Our review is unique because it focused on cancer screening and measurable outcomes based on a theoretical framework. In particular, this review elucidated that few decision aids on cancer screening actually evaluated their effect on a patient's entire decision-making process, including shared decisionmaking and reaching concordance with their clinician. Our review indicated areas in which further research is needed, as we detail below. Among the most important would be having a theoretical framework so that appropriate outcomes are measured, an objective assessment of shared decision-making, and attention to applicability in other settings.
Suggestions for Future Research
1) A strong theoretical framework should support the decision aid and guide its development as well as measurement outcomes. There should be a clear correlation between the theoretical framework and the measured outcomes. 2) There should be more studies that critically compare explicit versus implicit values clarification. 3) An objective measure of screening uptake (eg, paper chart review, extraction of electronic health record data) should be adopted to assess the effectiveness of the decision aid. 4) Shared decision-making between the patient and the clinician should be recorded and objectively measured by validated tools. 5) Other potential mediators that temporally occur after the patient's decision aid use, such as media and family influence, should be considered. 6) How decision aids would fare as a meaningful part of primary care practice should be assessed through their better integration into practice and a broader, practice-based approach to measure their effectiveness. 7) To address applicability in real-world settings, studies should continue to be performed in heterogeneous community practice settings, using practice-based research networks. 8) Long-term effectiveness and viability should be addressed, including the effect on repeated screening and cost-effectiveness and cost-benefit analyses. 9) With the advent of more options in breast and cervical cancer screening and the need for even better informed and shared decision-making in prostate cancer screening with the advent of conflicting guidelines, there are even more opportunities for decision aids to be useful in the setting of cancer screening.
Conclusions
Decision aids are here to stay. Although much research needs to be done to determine what really makes for an effective decision aid, practical applications are already occurring. Many decision aids are now available free of charge. Clinicians are encouraged to explore them, select those that fit best with their current understanding of the topic in question, and apply them to their practice workflow in a creative way. n
